Costs and benefits of whole-exome, whole-transcriptome sequencing versus 50-gene panels for genomic profiling in solid tumors.

Jesse D Ortendahl¹, Gebra Cuyun Carter², Eliza M Zantema¹, Jess R Hoag², Arthur Starodynov², Karen L White², Gargi D Basu², Anson Tharayanil², Jean-Paul De La O², David W Hall², Frederick L Baehner²

¹Stratevi, Boston, MA, USA.

²Exact Sciences Corporation, Madison, WI, USA.

PubMed DOI

Abstract

AIMS: The rapid development of therapies linked to molecular biomarkers has increased the importance of next-generation sequencing (NGS)-based tumor profiling to guide treatment decisions. Technology has enabled more comprehensive clinical testing; however, the optimal economic approach deserves investigation. This study evaluated the impact of testing using whole-exome, whole-transcriptome sequen…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.